Prelude Therapeutics Inc. — Q3 2022 Form 10-Q
Reporting period: Three and nine months ended September 30, 2022. Prelude is a clinical-stage oncology company with no product revenue to date; it funds drug discovery and clinical development primarily from capital raised through equity offerings.
Financial performance and liquidity
| Metric | Q3 2022 | Q3 2021 | Nine months 2022 | Nine months 2021 |
|---|---|---|---|---|
| Revenue | None | None | None | None |
| Research and development expense | $22.9m | $22.7m | $67.0m | $61.6m |
| General and administrative expense | $7.5m | $8.1m | $23.1m | $19.1m |
| Total operating expenses | $30.4m | $30.8m | $90.2m | $80.7m |
| Net loss | $30.0m | $30.7m | $86.8m | $78.9m |
| Net loss per share, diluted | $0.63 | $0.66 | $1.84 | $1.72 |
- At September 30, cash and cash equivalents were $52.0m and marketable securities were $172.0m, totaling $224.0m. Restricted cash was an additional $4.0m. Management estimated available cash, cash equivalents and marketable securities would fund operating and capital requirements into Q4 2024; this estimate depends on assumptions and could prove inaccurate.
- Nine-month operating cash use was $60.8m, versus $57.8m in 2021. Investing activities provided $80.3m, principally reflecting maturities of marketable securities; financing provided $0.7m, versus $162.9m in 2021, which included the prior-year public stock offering.
- Accumulated deficit was $305.9m. The company reported no credit facility or committed capital source, and no material borrowings are shown. Liabilities included a $1.4m operating lease liability and $3.4m of deferred state grant funds.
- There is no meaningful revenue-based margin measure because the company has no revenue. Nine-month stock-based compensation was $19.3m.
Changes versus comparable periods
- Q3 net loss narrowed by $0.7m year over year as total operating expenses declined $0.4m and other income increased $0.3m. Lower G&A, including lower stock-based compensation and expense management, more than offset a modest R&D increase.
- For the first nine months, net loss widened by $7.9m. Operating expenses rose $9.4m, including increases in discovery-program and internal costs, personnel-related G&A and stock-based compensation. Other income increased $1.5m, principally from Delaware grant income and investment interest.
- Marketable securities declined from $259.4m at year-end 2021 to $172.0m at September 30, 2022; cash and cash equivalents increased from $31.8m to $52.0m. The company recorded a $1.7m nine-month unrealized loss on marketable securities.
Outlook, programs and material items
- Management expects continued operating losses and significant R&D spending, and anticipates needing additional capital after the stated runway. Potential funding sources include equity, debt, collaborations and licensing; availability and terms are uncertain and could dilute shareholders or require surrendering rights.
- Pipeline plans stated in the filing included selecting a recommended Phase 2 dose for CDK9 candidate PRT2527 by year-end 2022, initiating a PRT3645 trial by year-end, and dosing the first patient in SMARCA2 degrader PRT3879 in Q1 2023. The company also described plans to evaluate MCL1 candidate PRT1419 in hematologic malignancies in 2023.
- Post-quarter development: In November 2022, Prelude announced it would discontinue internal development of its PRMT5 program, including PRT543 and PRT811, and focus on CDK9, MCL1, CDK4/6 and SMARCA2. The company reported two complete responses with PRT811, but said results did not meet its criteria for continued internal development. Both PRMT5 candidates were generally well tolerated in Phase 1 trials.
- Risks highlighted include clinical and regulatory failure or delay, patient enrollment, dependence on third-party CROs and manufacturers, competition, inflation and market volatility, COVID-19-related trial disruptions, intellectual-property protection, and the need for additional financing. Management said lead programs and research remained on track at the time, while noting limited trial delays had occurred.
- The Chestnut Run lease covers approximately 81,000 rentable square feet, has a 162-month initial term and three five-year extension options. Estimated rent payments begin in 2024; the lease had not commenced as of the reporting date. State grant funds are subject to repayment in specified circumstances, including insufficient eligible lab costs or leaving Delaware within five years of disbursement.
- The filing reports no material pending legal proceedings. Management concluded disclosure controls were effective at a reasonable assurance level and reported no material quarterly change in internal control over financial reporting.
Important facts for investors to verify
- Whether the November PRMT5 discontinuation changes expected spending, trial obligations, or the company’s Q4 2024 cash runway.
- Actual cash burn, investment maturities and portfolio values, and the assumptions supporting management’s runway estimate.
- Progress, safety and efficacy evidence for PRT1419, PRT2527, PRT3645 and PRT3879 against the stated development timelines.
- Whether the Chestnut Run lease commences as expected and the resulting lease obligations, alongside grant eligibility and any potential repayment obligations.
- Future financing needs and terms, including potential dilution, collaboration economics or restrictions associated with debt financing.